Dr. Loaiza-Bonilla is board certified in both medical oncology and hematology and specializes in treating gastrointestinal malignancies. He also has extensive experience in the diagnosis and treatment of neuroendocrine tumors (NETs) and genomic biomarker-driven cancers. Dr. Loaiza-Bonilla completed fellowship training in hematology and oncology at the University of Miami Miller School of Medicine in Miami, Florida and an internship and residency in internal medicine at Harbor Hospital Center, Johns Hopkins Hospital in Baltimore, Maryland. He received his medical degree from the Universidad Nacional de Colombia in Bogotá, Colombia.
Before joining Capital Health, Dr. Loaiza-Bonilla was vice chairman of the Department of Medical Oncology at Cancer Treatment Centers of America in Philadelphia, Pennsylvania, as well as enterprise director of research, where he provided leadership and expertise to their oncology trial portfolio across 5 cancer centers and over 70 NCTN and industry-sponsored clinical trials. His research has been extensively published in the most prominent journals and meetings in oncology, and he has been recipient of NIH funding to advance digital health and artificial intelligence tools for cancer research. He was also assistant professor of Clinical Medicine at the University of Pennsylvania School of Medicine; during that time, he completed his master’s degree in medical education at the same university and is currently assistant professor in the Department of Medicine at Drexel University College of Medicine, both in Philadelphia.
Throughout his distinguished academic and clinical career, Dr. Loaiza-Bonilla has held numerous leadership positions such as President of the Pennsylvania Society of Oncology and Hematology and President of the Board of Directors of the Global Alliance for Patient Access. In 2018, he was recognized as Philadelphia Business Journal’s Forty Under 40, in 2019 he was bestowed the Influencers of Healthcare Award – Outstanding Healthcare Provider award by the Philadelphia Inquirer, and in 2021 he was chosen as recipient of ’40 under 40 in Cancer’ accolade. He has also been selected in Castle Connolly’s and Philadelphia Magazine’s Top Doctors listing since 2018.